ATE224956T1 - Verfahren zur verstärkten expression von virusproteinen - Google Patents
Verfahren zur verstärkten expression von virusproteinenInfo
- Publication number
- ATE224956T1 ATE224956T1 AT93918614T AT93918614T ATE224956T1 AT E224956 T1 ATE224956 T1 AT E224956T1 AT 93918614 T AT93918614 T AT 93918614T AT 93918614 T AT93918614 T AT 93918614T AT E224956 T1 ATE224956 T1 AT E224956T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- enhanced expression
- virus proteins
- methods
- cell
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/921,807 US5474914A (en) | 1992-07-29 | 1992-07-29 | Method of producing secreted CMV glycoprotein H |
PCT/US1993/007299 WO1994003620A2 (en) | 1992-07-29 | 1993-07-29 | Method of increasing expression of viral proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE224956T1 true ATE224956T1 (de) | 2002-10-15 |
Family
ID=25446002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93918614T ATE224956T1 (de) | 1992-07-29 | 1993-07-29 | Verfahren zur verstärkten expression von virusproteinen |
Country Status (9)
Country | Link |
---|---|
US (2) | US5474914A (de) |
EP (2) | EP1298215A3 (de) |
JP (1) | JP3048387B2 (de) |
AT (1) | ATE224956T1 (de) |
AU (1) | AU680425B2 (de) |
CA (1) | CA2140531C (de) |
DE (1) | DE69332334T2 (de) |
DK (1) | DK0652966T3 (de) |
WO (1) | WO1994003620A2 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242567B1 (en) * | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
US6162620A (en) * | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
US6855316B1 (en) * | 1994-02-14 | 2005-02-15 | University Of Hawaii | Baculovirus produced Plasmodium falciparum vaccine |
US5470719A (en) * | 1994-03-18 | 1995-11-28 | Meng; Shi-Yuan | Modified OmpA signal sequence for enhanced secretion of polypeptides |
MY114769A (en) * | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
US5807557A (en) * | 1994-07-25 | 1998-09-15 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex |
US6156319A (en) * | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
US5742181A (en) * | 1996-06-04 | 1998-04-21 | Hewlett-Packard Co. | FPGA with hierarchical interconnect structure and hyperlinks |
US6461814B1 (en) * | 1997-01-15 | 2002-10-08 | Dominic G. Spinella | Method of identifying gene transcription patterns |
WO2000039311A1 (en) * | 1998-12-31 | 2000-07-06 | Advanced Research And Technology Institute | Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
US7108984B2 (en) * | 2000-01-12 | 2006-09-19 | Mount Sinai School Of Medicine | Methods of identifying modulators of the FGF receptor |
US20030100106A1 (en) * | 2000-02-08 | 2003-05-29 | Chang Sandra P. | Baculovirus produced Plasmodium falciparum vaccine |
US7015033B1 (en) * | 2000-05-25 | 2006-03-21 | Aventis Pasteur Limited | Co-expression of recombination proteins |
JP2005502350A (ja) * | 2001-09-06 | 2005-01-27 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | ヒト免疫不全ウイルスエンベロープ糖タンパク質変異体およびその使用 |
US20030199092A1 (en) * | 2002-01-11 | 2003-10-23 | The Regents Of The University Of California | Methods for increasing mRNA half-life in eukaryotic cells |
US20060051373A1 (en) * | 2002-04-05 | 2006-03-09 | Olson William C | Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods |
US7601491B2 (en) | 2003-02-06 | 2009-10-13 | Becton, Dickinson And Company | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US20080274134A1 (en) * | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
WO2006017724A1 (en) * | 2004-08-06 | 2006-02-16 | Becton, Dickinson And Company | Sequences and methods for detection of cytomegalovirus |
WO2007014123A2 (en) * | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
EP2040747A4 (de) * | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | Lösliche stabilisierte trimere hiv-hüllproteine und ihre verwendung |
CA2667358A1 (en) * | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
EP2318529B1 (de) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Muteine in der sauren region der extrazellulären domäne von fgfr |
US9279013B2 (en) | 2008-10-10 | 2016-03-08 | Amgen Inc. | FGF-21 mutants comprising polyethylene glycol and uses thereof |
US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
CN107188950B (zh) | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | Fgf21突变体及其用途 |
WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
ES2600631T3 (es) | 2009-11-13 | 2017-02-10 | Five Prime Therapeutics, Inc. | Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2 |
US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
EP3187585A1 (de) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
LT3981427T (lt) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
MX363307B (es) | 2010-10-11 | 2019-03-20 | Novartis Ag Star | Plataformas para suministro de antigenos. |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
EP2502631A1 (de) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immunsuppressor und seine Verwendung |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
CA2855818A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression |
SG11201408328VA (en) * | 2012-07-06 | 2015-02-27 | Novartis Ag | Complexes of cytomegalovirus proteins |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN108300731A (zh) * | 2018-02-02 | 2018-07-20 | 暨南大学 | 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340740C (en) * | 1987-12-08 | 1999-09-14 | Eileen R. Mulvihill | Co-expression in eukaryotic cells |
KR0163441B1 (ko) * | 1989-11-17 | 1998-12-01 | 로버트 에이 아미테이지 | 트리시클릭[6,5,5]/[6,6,5]-융합 옥사졸리디논 항균제 |
EP0541721A4 (en) * | 1990-08-02 | 1993-12-29 | Chiron Corporation | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
WO1992006212A1 (en) * | 1990-09-28 | 1992-04-16 | Smithkline Beecham Corporation | Enhanced expression of viral proteins in drosophila cells |
EP0509841A3 (en) * | 1991-04-18 | 1993-08-18 | Tonen Corporation | Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system |
NL9102009A (nl) * | 1991-11-29 | 1993-06-16 | Stichting Katholieke Univ | Produktie van bioactieve peptiden met recombinante cellen. |
-
1992
- 1992-07-29 US US07/921,807 patent/US5474914A/en not_active Expired - Lifetime
-
1993
- 1993-07-29 WO PCT/US1993/007299 patent/WO1994003620A2/en active IP Right Grant
- 1993-07-29 EP EP02078729A patent/EP1298215A3/de not_active Ceased
- 1993-07-29 DE DE69332334T patent/DE69332334T2/de not_active Expired - Lifetime
- 1993-07-29 JP JP6505519A patent/JP3048387B2/ja not_active Expired - Fee Related
- 1993-07-29 CA CA002140531A patent/CA2140531C/en not_active Expired - Lifetime
- 1993-07-29 EP EP93918614A patent/EP0652966B1/de not_active Expired - Lifetime
- 1993-07-29 AT AT93918614T patent/ATE224956T1/de active
- 1993-07-29 DK DK93918614T patent/DK0652966T3/da active
- 1993-07-29 AU AU48008/93A patent/AU680425B2/en not_active Expired - Fee Related
-
1995
- 1995-05-16 US US08/441,944 patent/US5767250A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0652966B1 (de) | 2002-09-25 |
AU4800893A (en) | 1994-03-03 |
DE69332334D1 (de) | 2002-10-31 |
AU680425B2 (en) | 1997-07-31 |
JP3048387B2 (ja) | 2000-06-05 |
DK0652966T3 (da) | 2003-02-03 |
EP1298215A3 (de) | 2007-09-26 |
EP0652966A1 (de) | 1995-05-17 |
JPH07509370A (ja) | 1995-10-19 |
WO1994003620A2 (en) | 1994-02-17 |
EP1298215A2 (de) | 2003-04-02 |
DE69332334T2 (de) | 2003-08-07 |
US5767250A (en) | 1998-06-16 |
CA2140531C (en) | 2000-03-28 |
US5474914A (en) | 1995-12-12 |
WO1994003620A3 (en) | 1994-05-11 |
CA2140531A1 (en) | 1994-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE224956T1 (de) | Verfahren zur verstärkten expression von virusproteinen | |
DE3874798T2 (de) | Therapeutisches proteinagens in form von aerosol. | |
FI101381B1 (fi) | Nukleotidisekvenssi ja menetelmä polypeptidin HSA(1-387) tuottamiseksi | |
EP0259475A4 (de) | Rekombinanter menschlicher endothelzellenwachstumsfaktor. | |
DE3382760T2 (de) | Herstellung von funktionellen menschlichen Urokinasepolypeptiden. | |
DK106288D0 (da) | Osteoinduktive praeparater | |
ATE423204T1 (de) | Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln | |
ATE171710T1 (de) | Hcv peptidantigene und verfahren zur bestimmung von hcv | |
DE69734464D1 (de) | Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon | |
ATE125298T1 (de) | Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression. | |
ATE65506T1 (de) | Verfahren zur stabilisierung von proteinen. | |
DE59006998D1 (de) | Verfahren zur herstellung von hirudin. | |
DE3883596T2 (de) | Reinigung von rekombiniertem Hepatitis-B-Oberflächen-Antigen. | |
DE3485883D1 (de) | Rekombinante materialien und verfahren zur herstellung von menschliche konnektive gewebe aktivierende peptide iii und deren analoge. | |
ATE79651T1 (de) | Rekombinante materialien und verfahren zur herstellung von menschliche konnektive gewebe aktivierende peptide iii und deren analoge. | |
PT89041A (pt) | Metodo de preparacao de diagnosticos e vacinas nanbv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0652966 Country of ref document: EP |